Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CXCR4 | P61073 | 10/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | CCR2 | P41597 | 1/20 | 0.46 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11518108 | 0.88 | FAAH (0.54) | CYP2D6CXCR4CHRM2CHRM1MEN1 | |
| SCHEMBL24283140 | 0.85 | TSHR (0.49) | CYP2D6CHRM2MEN1KMT2AHRH3 | |
| SCHEMBL3143023 | 0.83 | CYP2D6 (0.68) | CYP2D6CXCR4CHRM2CHRM1MEN1 | |
| SCHEMBL24283104 | 0.81 | SMN1; SMN2 (0.57) | MEN1KMT2AFAAH | |
| SCHEMBL11518878 | 0.81 | CXCR4 (0.46) | CYP2D6CXCR4CHRM2CHRM1MEN1 | |
| SCHEMBL11518881 | 0.81 | CYP2D6 (0.60) | CYP2D6CXCR4CHRM2CHRM1MEN1 | |
| SCHEMBL23943551 | 0.80 | SMN1; SMN2 (0.41) | CYP2D6MEN1KMT2AFAAH | |
| SCHEMBL592970 | 0.77 | KDM4E (0.58) | CYP2D6CHRM1MEN1KMT2AADRA2C | |
| SCHEMBL24282068 | 0.77 | CYP2D6 (0.40) | CYP2D6CXCR4MEN1KMT2AADRA2C | |
| SCHEMBL11459340 | 0.77 | CXCR4 (0.46) | CYP2D6CXCR4CHRM2CHRM1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021208963-A1 | BCL-2 INHIBITOR | BEIGENE, LTD. (KY) | 2021-10-21 | — | — | WO | disclosed |
| US-10344021-B2 | Process for the separation of enantiomers of piperazine derivatives | ASCENEURON S A (CH) | 2019-07-09 | — | — | US | disclosed |
| WO-2017144635-A1 | PROCESS FOR THE SEPARATION OF ENANTIOMERS OF PIPERAZINE DERIVATIVES | ASCENEURON S. A. (CH) | 2017-08-31 | — | — | WO | disclosed |
| EP-1781661-B1 | VASOPRESSIN V1A ANTAGONISTS | VANTIA LTD (GB) | 2017-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344021-B2 | Process for the separation of enantiomers of piperazine derivatives | CYP3A5, CYP4Z1, HTR5A | CYP2D6 134/4885CXCR4 241/4885CHRM2 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.